BIOLASE (NASDAQ:BIOL) Earns Sell Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of BIOLASE (NASDAQ:BIOL) in a report published on Saturday. The firm issued a sell rating on the medical technology company’s stock.

Other analysts also recently issued reports about the stock. Ascendiant Capital Markets cut their price objective on shares of BIOLASE from $3.50 to $2.00 and set a “buy” rating on the stock in a research report on Tuesday, September 3rd. Benchmark reiterated a “speculative buy” rating and issued a $0.40 target price on shares of BIOLASE in a research note on Wednesday, October 2nd.

BIOLASE Stock Performance

BIOLASE stock opened at $0.01 on Friday. BIOLASE has a 12 month low of $0.02 and a 12 month high of $1.94. The company has a market capitalization of $267,256.00, a price-to-earnings ratio of 0.00 and a beta of 0.67. The business’s fifty day simple moving average is $0.01 and its two-hundred day simple moving average is $0.05.

About BIOLASE

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.